149 related articles for article (PubMed ID: 30187562)
1. Bugs and drugs: Predicting response to therapy.
Ananthakrishnan AN
J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():27. PubMed ID: 30187562
[No Abstract] [Full Text] [Related]
2. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
[TBL] [Abstract][Full Text] [Related]
3. Ulcerative Colitis in Adults.
Glick LR; Cifu AS; Feld L
JAMA; 2020 Sep; 324(12):1205-1206. PubMed ID: 32857108
[No Abstract] [Full Text] [Related]
4. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.
Shaw KA; Bertha M; Hofmekler T; Chopra P; Vatanen T; Srivatsa A; Prince J; Kumar A; Sauer C; Zwick ME; Satten GA; Kostic AD; Mulle JG; Xavier RJ; Kugathasan S
Genome Med; 2016 Jul; 8(1):75. PubMed ID: 27412252
[TBL] [Abstract][Full Text] [Related]
5. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
6. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.
Rogler G; Aldeguer X; Kruis W; Lasson A; Mittmann U; Nally K; Peyrin-Biroulet L; Schoepfer A; Vatn M; Vavricka S; Logan R
J Crohns Colitis; 2013 Sep; 7(8):670-7. PubMed ID: 23517932
[No Abstract] [Full Text] [Related]
7. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Management of Crohn Disease.
Feld L; Glick LR; Cifu AS
JAMA; 2019 May; 321(18):1822-1823. PubMed ID: 30969326
[No Abstract] [Full Text] [Related]
9. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
[TBL] [Abstract][Full Text] [Related]
11. [Anti tumor necrosis factor alpha antibody: infliximab].
Arimitsu S; Ito H
Nihon Rinsho; 2012 Feb; 70 Suppl 1():329-32. PubMed ID: 23126112
[No Abstract] [Full Text] [Related]
12. [Laboratory values, endoscopy and new imaging. What is the status of diagnosis?].
Herfarth H
Internist (Berl); 2002 Nov; 43(11):1354-8, 1361-6. PubMed ID: 12524916
[No Abstract] [Full Text] [Related]
13. [Calprotectin in feces a well-documented marker of gastrointestinal inflammation. Indicates disease intensity--normalization of values predict mucosal healing].
Lasson A
Lakartidningen; 2010 Oct 27-Nov 2; 107(43):2645-9. PubMed ID: 21137533
[No Abstract] [Full Text] [Related]
14. What is the role and significance of serum and stool biomarkers in the diagnosis of IBD?
Palmon R; Brown SJ; Abreu MT
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S187-9. PubMed ID: 18816678
[TBL] [Abstract][Full Text] [Related]
15. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy.
Gorbach SL; Nahas L; Plaut AG; Weinstein L; Patterson JF; Levitan R
Gastroenterology; 1968 Apr; 54(4):575-87. PubMed ID: 4385122
[No Abstract] [Full Text] [Related]
16. Commentary: is Faecalibacterium prausnitzii a potential treatment for maintaining remission in ulcerative colitis?
Siaw YH; Hart A
Aliment Pharmacol Ther; 2013 Sep; 38(5):551. PubMed ID: 23937459
[No Abstract] [Full Text] [Related]
17. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
[TBL] [Abstract][Full Text] [Related]
18. [Biologicals in gastroenterology: TNF-blockers].
Scharl M; Rogler G
Dtsch Med Wochenschr; 2010 Nov; 135(45):2243-52. PubMed ID: 21046532
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
20. A microbial signature for Crohn's disease.
Pascal V; Pozuelo M; Borruel N; Casellas F; Campos D; Santiago A; Martinez X; Varela E; Sarrabayrouse G; Machiels K; Vermeire S; Sokol H; Guarner F; Manichanh C
Gut; 2017 May; 66(5):813-822. PubMed ID: 28179361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
